-+ 0.00%
-+ 0.00%
-+ 0.00%

Entrada Therapeutics Highlights Advancement Of RNA-Based Neuromuscular And Ocular Disease Programs And Cash Runway Into Q3 2027

Benzinga·01/08/2026 12:09:54
Listen to the news

-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 –

-- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit global regulatory applications for ENTR-601-51 in 2026 –

-- Expands pipeline with selection of ENTR-801 as first clinical candidate in ocular diseases for the treatment of Usher syndrome type 2A and expects to nominate second clinical candidate in 2026 –

-- Cash runway into Q3 2027 –

-- Entrada to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET) --